IAP Overexpression and Cervical Cancer Recurrence in Radio-Chemotherapy Patients
Official title: Evaluation of the Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on the 24-month Recurrence Rate in Locally Advanced Cervical Cancer
Run by Centre Hospitalier Universitaire de Nīmes · NCT06147960 · Data updated 2026-11-12
This study checks whether higher levels of inhibitors of apoptosis proteins (IAPs) in cervical cancer patients treated with radio-chemotherapy can predict cancer coming back within 2 years.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 180 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Nīmes Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Nîmes, Gard) |
| Status | Recruiting |
| Started | September 26, 2024 |
| Main results expected | May 2027 |
| Study ends | November 2027 |
| Registry record updated | June 22, 2026 |
| Trial ID | NCT06147960 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with locally advanced cervical carcinoma (FIGO Ib-IVb) treated with exclusive radio-chemotherapy and having at least 2 years of follow-up and available pre-treatment biopsy.
✕Probably not a fit
Patients without overexpression of IAPs or those not following the expected recurrence pattern may derive no direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study examines locally advanced cervical cancer patients who received exclusive radiotherapy with chemotherapy. It tests whether overexpression of IAPs (such as XIAP, cIAP1, and cIAP2) in initial biopsy samples is linked to higher local recurrence at 24 months. Immunohistochemistry is used to measure IAP levels. The goal is to identify potential prognostic markers that could guide future treatment choices. The study is conducted at CHU de Nîmes with collaboration from Institut du Cancer de Montpellier - Val d'Aurelle and includes patients who meet specific clinical criteria.
Why it matters
Potential benefit: If overexpression of IAPs is linked to recurrence, this could help personalize follow-up and consider alternative strategies for high-risk patients.
How similar studies have gone: Prior research in other cancers suggests IAPs can influence treatment resistance, but findings in cervical cancer are exploratory and not yet definitive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients treated with the exclusive radio-chemotherapy combination for locally advanced cervical carcinoma (stage Ib-IVb according to FIGO classification). * Patients aged ≥ 18 years. * Patients with a minimum of 2 years post-treatment follow-up. * Patients for whom the initial biopsy specimen (before treatment) is available. * Patients who have not indicated that they do not wish to participate in the study. * Patients affiliated to or benefiting from a health insurance scheme. Exclusion Criteria: * Patients under court protection, guardianship or curatorship.
Where it's running
-
CHU de Nîmes
Nîmes, Gard, France Recruiting
Study contacts
- Principal investigator: Alexandre TAYART de BORMS, Interne — Nîmes University Hospital
- Study coordinator: Frédéric FITENI, Dr.
- Email: frederic.fiteni@chu-nimes.fr
- Phone: +334.34.03.46.69
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based precision oncology clinical trial matching and registry
This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.
-
Shorter pelvic radiotherapy after surgery for cervical or endometrial cancer
A randomized study tests whether a shorter course of postoperative whole-pelvic radiotherapy can be as safe and effective as the standard longer schedule for women with cervical or endometrial cancer.
-
Late radiation side effects after postoperative IMRT and brachytherapy for cervical and endometrial cancer
This project will see how often and how severe late gastrointestinal and urinary side effects are in people with cervical or endometrial cancer who received postoperative IMRT and/or brachytherapy at Tata Memorial Hospital.
-
Comparing clinic-only versus clinic plus community outreach to offer HPV self-collection for cervical screening in women with HIV
This project will test whether adding community health worker outreach to clinic services helps more women living with HIV complete HPV self-collection for cervical screening.
-
Outcomes for Oligometastatic and Oligorecurrent Cervical Cancer
This registry will see if adding local treatments such as radiation or surgery to standard systemic therapy helps people with oligo‑metastatic or oligo‑recurrent cervical cancer live longer or avoid progression.
-
Hyaluronic acid gel spacer to protect nearby organs during cervical cancer radiation
This pilot tests a hyaluronic acid gel spacer (Barrigel) to see if it helps people with cervical cancer receiving chemoradiotherapy and brachytherapy by creating space between the tumor and nearby organs.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.